Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers, and its news flow reflects both scientific progress and capital markets activity. The company focuses on CAR T-cell therapies and an HSV-1 oncolytic virus, with programs aimed at malignant glioma, recurrent glioblastoma (GBM), high-grade astrocytomas, and related brain tumors.
News about Mustang Bio often centers on pipeline milestones, including updates on MB-101, an IL13Rα2-targeted CAR T-cell therapy, and MB-108, an HSV-1 oncolytic virus. The company has reported U.S. Food and Drug Administration Orphan Drug Designations for MB-108 in malignant glioma and MB-101 in recurrent diffuse and anaplastic astrocytoma and glioblastoma. Mustang Bio also highlights the MB-109 regimen, which combines MB-101 and MB-108 to reshape the tumor microenvironment and potentially enhance CAR-T activity in recurrent GBM and high-grade astrocytomas.
Investors following MBIO news will also see listing and financing developments, such as reverse stock split announcements, Nasdaq compliance updates on minimum bid price and stockholders’ equity requirements, and details of public offerings and warrant exercises. These items provide context on Mustang Bio’s access to capital and its efforts to maintain its Nasdaq Capital Market listing.
This news page aggregates Mustang Bio’s press releases and related coverage, giving readers a single place to review regulatory designations, clinical trial updates, facility and operational changes, and securities offerings. For those tracking MBIO, revisiting this page can help monitor how Mustang Bio’s cell therapy programs and corporate actions evolve over time.
Mustang Bio, Inc. (NASDAQ: MBIO) reported financial results for Q1 2022, revealing a net loss of $19.8 million ($0.20 per share), up from $15.0 million ($0.19 per share) a year earlier. As of March 31, 2022, cash reserves rose to $123.2 million, an increase of $12.6 million year-to-date. Significant clinical data were presented at major conferences, showing a 96% overall response rate for MB-106 in B-cell NHL and CLL. Upcoming presentations are scheduled for EHA2022 and ASGCT. Mustang aims to start several clinical trials for MB-106 and MB-107 later this year, reflecting strong progress in its development pipeline.
Mustang Bio (MBIO) announced results from the Phase 1/2 trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory follicular lymphoma (FL), to be presented at EHA2022. Dr. Mazyar Shadman will provide updated patient data, indicating a favorable safety profile and notable response rates. The trial is progressing with expanding enrollment criteria, which includes CAR T naïve patients and those previously treated. Mustang anticipates dosing the first patient in a multicenter trial evaluating MB-106's safety and efficacy this quarter.
Mustang Bio announced significant interim Phase 1/2 clinical trial results for its lentiviral gene therapy, MB-107, targeting X-linked severe combined immunodeficiency (XSCID). The data highlights a cohort of 23 infants, all still alive, with 20 showing recovery from pre-existing infections and normal growth. Seventeen of 18 patients with over six months of follow-up achieved robust immune reconstitution. The presentation will be held at the ASGCT Annual Meeting on May 19, 2022, with plans to initiate a pivotal Phase 2 trial later in 2022.
Mustang Bio, Inc. (NASDAQ: MBIO) announced promising interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The study demonstrated a 96% overall response rate and a 72% complete response rate, with a favorable safety profile across all 25 patients. Notably, previous CAR T therapy patients also responded well. The company plans to dose the first patient in a multicenter trial this quarter, indicating potential for outpatient treatment.
Mustang Bio (NASDAQ: MBIO) announced that Dr. Mazyar Shadman will present interim data on MB-106, a CD20-targeted CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, at two key conferences. The presentations will occur at the 2022 Tandem Meetings (April 23-26) and iwCAR-T (April 28-May 1). Initial findings indicate promising clinical efficacy and safety of MB-106, which is in a Phase 1/2 trial at Fred Hutch. The company plans to start a multicenter trial under its IND soon. The autologous CAR-T therapy was collaboratively developed with Fred Hutch.
Mustang Bio (NASDAQ: MBIO) announced positive interim results from ongoing Phase 1 clinical trials of MB-101 (a CAR T cell therapy) and MB-108 (an oncolytic virus) for recurrent glioblastoma (rGBM). Research presented by Dr. Christine Brown at the AACR Annual Meeting 2022 indicates these therapies are well tolerated, with preliminary safety data supporting the development of a combination therapy, MB-109, which aims to enhance treatment efficacy. Mustang plans to file an Investigational New Drug application for MB-109 later this year, aiming to address the challenges of rGBM treatment.
Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical firm, announced its participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. Mustang’s management will present a corporate overview and join a panel discussion on April 6 at 1:30 p.m. ET. Interested parties can register for the event here. A webcast will be available for 30 days post-event on the Investor Relations section of Mustang’s website.
Mustang Bio, Inc. (NASDAQ: MBIO) reported its financial results and corporate highlights for 2021, achieving significant advancements in cell and gene therapies. The FDA approved two IND applications for pivotal trials of MB-107 and MB-106, targeting severe combined immunodeficiency and non-Hodgkin lymphoma, respectively. The company raised $2 million from the National Cancer Institute to support its trials. Despite a net loss of $66.4 million, liquidity improved to $110.6 million. With several upcoming clinical trials and promising interim data, Mustang aims for further growth in 2022.
Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company, announced participation in three virtual investor conferences in March 2022. CEO Manuel Litchman will engage in a fireside chat at Oppenheimer’s Virtual Healthcare Conference on March 15 at 4:00 p.m. ET. Additionally, Mustang will present on-demand at H.C. Wainwright’s Gene Therapy Conference starting March 30 and participate in a panel at Cantor Fitzgerald’s Rare Disease Summit the same day. These events highlight Mustang's commitment to advancing cell and gene therapies for various diseases.
Mustang Bio (NASDAQ: MBIO) announced that an abstract regarding Phase 1 trials of its oncolytic viral and CAR T-cell therapies for glioblastoma (GBM) has been selected for a late-breaking poster presentation at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. City of Hope’s Dr. Christine Brown will present the data, highlighting the combination of MB-108 oncolytic virus and MB-101 CAR T-cell therapy, together referred to as MB-109. An Investigational New Drug application for MB-109 is anticipated later this year.